Conditions: Irritable Bowel Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 155
Healthy volunteers: no

Brief summary:
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.

Detailed description:

Arms:
arm 1: A high dose of LX1031; daily oral intake for 28 days arm 2: A low dose of LX1031; daily oral intake for 28 days arm 3: Matching placebo dosing with daily oral intake

Interventions: intervention 1: LX1031 High Dose intervention 2: LX1031 Low Dose intervention 3: Placebo
Intervention descriptions: intervention 1: A high dose of LX1031; daily oral intake for 28 days intervention 2: A low dose of LX1031; daily oral intake for 28 days. intervention 3: Matching placebo dosing with daily oral intake

Protocol document: